Gourzis Philippos, Polychronopoulos Panagiotis, Papapetropoulos Spiridon, Assimakopoulos Konstantinos, Argyriou Andreas A, Beratis Stavroula
Department of Psychiatry, Medical School of Patras University, Rion-Patras, Greece.
Clin Neuropharmacol. 2005 Jul-Aug;28(4):195-6. doi: 10.1097/01.wnf.0000174933.89758.c9.
The authors report 2 patients with schizophrenia who developed focal tardive dystonia secondary to treatment with atypical antipsychotics (risperidone, olanzapine). When quetiapine was gradually introduced and other antipsychotics were discontinued, these patients experienced remarkable and sustained improvement of their dystonic symptoms, without loss of psychotic symptom control. The mechanism by which quetiapine may improve tardive dystonia caused by other atypical antipsychotics is unclear. Due to its receptor and pharmacologic profile, quetiapine is the atypical antipsychotic that is most similar to clozapine (without its hematologic side effects), which leads the authors to consider it for the treatment of tardive movement disorders.
作者报告了2例精神分裂症患者，他们在接受非典型抗精神病药物（利培酮、奥氮平）治疗后出现了局灶性迟发性肌张力障碍。当逐渐引入喹硫平并停用其他抗精神病药物时，这些患者的肌张力障碍症状得到了显著且持续的改善，同时并未丧失对精神病症状的控制。喹硫平改善其他非典型抗精神病药物所致迟发性肌张力障碍的机制尚不清楚。由于其受体和药理学特性，喹硫平是与氯氮平最相似的非典型抗精神病药物（无血液学副作用），这使得作者考虑将其用于治疗迟发性运动障碍。
